Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Cash & Equivalents (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Cash & Equivalents for 6 consecutive years, with $34.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 48.5% to $34.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $34.3 million, a 48.5% decrease, with the full-year FY2025 number at $34.3 million, down 48.5% from a year prior.
  • Cash & Equivalents was $34.3 million for Q4 2025 at Lexicon Pharmaceuticals, down from $49.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $102.3 million in Q2 2023 to a low of $21.1 million in Q3 2023.
  • A 3-year average of $47.8 million and a median of $35.1 million in 2024 define the central range for Cash & Equivalents.
  • Biggest YoY gain for Cash & Equivalents was 271.12% in 2024; the steepest drop was 65.17% in 2024.
  • Lexicon Pharmaceuticals' Cash & Equivalents stood at $22.5 million in 2023, then surged by 196.71% to $66.7 million in 2024, then plummeted by 48.5% to $34.3 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Cash & Equivalents are $34.3 million (Q4 2025), $49.7 million (Q3 2025), and $21.4 million (Q2 2025).